- Published at
- by seekingalpha.com
positive
positive
Cellectis S.A announces potential resale of up to 44M shares (NASDAQ:CLLS)
Cellectis S.A announces potential resale of 44M shares by AstraZeneca Holdings B.V.
News for Cellectis S.A. (CLLS)
- Published at
- by investing.com
mixedmixedCellectis stock plunges to 52-week low at $1.52 amid market challenges By Investing.com
Cellectis stock plunges to 52-week low at $1.52 amid market challenges- Published at
- by seekingalpha.com
neutralneutralCellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ETCompany ParticipantsArthur Stril - Interim Chief Financial...- Published at
- by globenewswire.com
mixedmixedGenome Editing Market to Surpass Market Valuation of USD 31.15 Billion by 2031 | SkyQuest Technology
Global Genome Editing Market size was valued at USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast...- Published at
- by seekingalpha.com
mixedmixedCellectis: Cheap With Promising But Speculative Cancer Therapies (NASDAQ:CLLS)
Cellectis S.A. offers innovative CAR-T therapies for cancer with promising pipeline candidates like UCART22 for ALL and CLLS52. Learn more on CLLS stock here.- Published at
- by globenewswire.com
mixedmixed[Latest] Global Genetic Engineering Market Size/Share Worth USD 2,917.2 Million by 2033 at a 6.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Gro
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Genetic Engineering...- Published at
- by globenewswire.com
positivepositiveGenome Editing Market to Grow at CAGR of 17% through 2033 - Rise in Demand for Synthetic Genes
The high prevalence of infectious diseases and cancer, coupled with rapid advancements in sequencing and genome editing technologies, is driving...- Published at
- by globenewswire.com
neutralneutralCellectis publie ses résultats financiers du deuxième trimestre 2024
Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la FDA et statut de médicament orphelin accordé par la...- Published at
- by seekingalpha.com
mixedmixedCaribou: Analyzing HLA Matching And CB-010's Clinical Performance (NASDAQ:CRBU)
Caribou Biosciences, Inc.'s disappointing results in Phase 1 clinical trial for CB-010, led to a 45% stock price decline. Learn more on CRBU stock here.- Published at
- by globenewswire.com
mixedmixedGlobal Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%
The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market Size is Expected to Reach USD 34.75...- Published at
- by rttnews.com
mixedmixedPre-market Movers: PIXY, BWAQ, TH, QSG, MOLN…
Florida-based ShiftPixy, Inc. (PIXY) is up over 30 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.- Published at
- by globenewswire.com
neutralneutralCellectis publie ses résultats financiers du premier trimestre 2024
• Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca • Situation de trésorerie de 143 millions de dollars au 31 mars...- Published at
- by globenewswire.com
mixedmixedCellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash...- Published at
- by globenewswire.com
mixedmixedGlobal Gene Therapy Market Size to Worth USD 49.21 Billion by 2032 | CAGR of 20.46%
The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market Size is expected to reach USD 49.21...- Published at
- by rttnews.com
mixedmixedPre -market Movers: CLLS, PAYC, WE, IRIX, GDEV…
Cellectis S.A. (CLLS) is up over 168% in Wednesday's pre-market trading. Here is the list of the other major pre-market movers..- Published at
- by benzinga.com
mixedmixedWhy Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Brainstorm Cell (NASDAQ:BCLI), Big 5 Sporting Goods (NASDAQ:BGFV)
Gainers- Published at
- by globenewswire.com
mixedmixedDelveInsight Evaluates a Robust Antibody-drug Conjugates in Oncology Clinical Trial Pipeline as 30+ Influential Pharma Players to Set Foot in the 7MM
The introduction of ADCs into the market and the promising clinical results of more ADC prospects have increased industry interest in ADCs as a treatment...- Published at
- by rttnews.com
mixedmixedPre-market Movers: GENE, RSLS, BMEA, EDBL, MDXH…
The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET)..- Published at
- by benzinga.com
mixedmixedWhy Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket - Aeglea BioTherapeutics (NASDAQ:AGLE), Aethlon Medical (NASDAQ:AEMD)
Gainers- Published at
- by marketscreener.com
mixedmixed